57 results about "Macular oedema" patented technology

Disclosed herein are compositions comprising one or more antibodies that specifically bind active plasma kallikrein (e.g., human plasma kallikrein) and methods of using such compositions for the treatment of retinal diseases, such as diabetic macular edema.

The invention provides an automatic screening method for diabetic macular edema based on transfer learning, which comprises the following steps: marking whether diabetic macular edema exists through an optical coherence tomography image and fundus color photograph; extracting eye features of a patient by using the trained deep residual neural artificial intelligence model, classifying whether diabetic macular edema exists according to the eye features, and performing polarity adjustment on the deep residual neural artificial intelligence model by using fundus color photograph data set trainingthrough a transfer learning technology; and obtaining a final intelligent screening model of diabetic macular edema based on fundus color photograph. The optical coherence tomography image and the fundus color photograph are used for identifying and classifying patients suffering from diabetic macular edema or not through the fundus color photograph-based intelligent screening model for diabeticmacular edema, so that the screening accuracy and the working efficiency of diabetic macular edema high-risk groups can be improved, and the expenditure of disease diagnosis and treatment of the patients is also reduced; therefore, more patients can be diagnosed and treated in time.

The invention provides application of total flavones of hippophae rhamnoides in preparation of treating diabetic retinopathy. The invention also provides a medicine composition for treating the diabetic retinopathy. The medicinal flavonoid compound can be used for resisting the oxidative damage of hydrogen peroxide, improving the activity of cells as well as the oxidation reduction function, and bringing protection to the retinal pigment epithelium (RPE), so that photoreceptor cells can be protected, the macular oedema is reduced, the vision is improved, and the total flavones of hippophae rhamnoides are expected to be developed into a new medicine for treating the diabetic retinopathy.

The invention belongs to the field of the medical technology, and particularly relates to traditional Chinese medicine for treating diabetes mild macular oedema. The traditional Chinese medicine includes the following traditional Chinese medicine bulk drugs of, by weight, 8-16 parts of American ginseng, 8-16 parts of atractylodes macrocephala koidz, 8-16 parts of astragalus membranaceus, 11-19 parts of poria cocos, 11-19 parts of cortex periplocae, 8-16 parts of rhizoma atractylodis, 8-16 parts of mangnolia officinalis, 8-16 parts of leonurus, 8-16 parts of cowherb seeds, 2-4 parts of semen lepidii, 5-13 parts of exocarpium, 5-13 parts of platycodon grandiflorum, 5-13 parts of prunella vulgaris and 8-16 parts of eriocaulon cinereum. By the adoption of the traditional Chinese medicine, absorption of the macular oedema can be prompted, restoration of the retina form is assisted, eyesight is effectively improved, and the visual function is improved.

The present invention relates to compounds of general formula (i) having an oxime moiety or a pharmaceutically acceptable salt, hydrate or solvate thereof and its use for inhibiting semicarbazide-sensitive amine oxidase (SSAO), also known as vascular adhesion protein-1 (VAP-1), a pharmaceutical composition comprising the compound or a salt, hydrate or solvate thereof as an active ingredient, a method for the prevention or the treatment of a SSAO/VAP-1 related disease, said diseases including acute or chronic inflammatory diseases, diseases related to carbohydrate metabolism, diabetes-associated complications, diabetic retinopathy and macular oedema, diseases related to adipocyte or smooth muscle dysfunctions, neurodegenerative diseases and vascular diseases.

The invention discloses an eyesight-improving decoction for treating diabetic retinopathy, which is prepared from the traditional Chinese raw material medicines comprising, by weight, 10-30 parts of astragalus membranaceus, 10-20 parts of codonopsis pilosula, 10-20 parts of poria cocos, 10-30 parts of salviae miltiorrhizae, 10-20 parts of kudzu roots, 5-15 parts of rhizoma anemarrhenae, 10-20 parts of angelica sinensis, 10-20 parts of white peony roots, 10-20 parts of rhizoma alismatis, 10-30 parts of semen plantaginis, 10-20 parts of rhizoma imperatae, 5-15 parts of cacumen biotae, 5-10 parts of honey-fried liquorice, 10-20 parts of radix rehmanniae preparata, 10-20 parts of fructus lycii, 10-20 parts of chinese yam, 10-20 parts of chrysanthemum, 5-15 parts of butterflybush flower, 5-15 parts of fructus leonuri and 10-20 parts of herba lycopi. The raw material medicines are combined to achieve the effects of boosting qi and activating blood, promoting urination and tonifying kidney, and improving eyesight. The decoction can reduce retinal hemorrhage and exudation, can promote absorption thereof and can promote absorption of macular oedema after retinal photocoagulation operation.

[Problem] To provide an anti-human Tie2 antibody which prevents or treats diabetic macular edema, diabetic retinopathy, or critical limb ischaemia by binding to human Tie2 and activating human Tie2. [Solution] The inventors of the present invention studied anti-human Tie2 antibodies and have provided an anti-human Tie2 antibody including four heavy chain variable regions and four light chain variable regions. The heavy chain variable regions comprise an amino acid sequence from amino acid no. 1 to 122 of SEQ ID NO:2, and the light chain variable regions comprise an amino acid sequence from amino acid No. 1 to 113 of SEQ ID NO:4. One of the heavy chain variable regions and one of the light chain variable regions constitute one antigen-binding site, and the antibody includes four antigen-binding sites.

The invention provides an ophthalmic preparation for treating macular edema, optic neuritis and non-infectious entophthalmia. The ophthalmic preparation is composed of an active ingredient for treating eye diseases and an ophthalmic preparation carrier or auxiliary material; the active ingredientfor treating the eye diseases is a glucocorticoid medicine and/or a non-steroidal medicine; the ophthalmic preparation carrier or auxiliary material comprises the following ingredients: a surfactant, an ionic polymer and a solvent, or the ophthalmic preparation carrier or auxiliary material contains the following ingredients: povidone with low polymerization degree, povidone with medium polymerization degree and a solvent. The ophthalmic preparation can carry (wrap) the glucocorticoid and/or the non-steroidal medicines to penetrate through the anterior segment of the eye and be conveyed to the posterior segment of the eye to treat the macular edema, the optic neuritis and the non-infectious entophthalmiain an eye drop administration mode, and the ophthalmic preparation has extremely excellent clinical use value and very positive social significance.

The invention provides buffered aqueous formulations of bevacizumab. The invention further provides methods of making buffered formulations of bevacizumab. The invention provides methods of treating eye disorders, particularly wet age-related macular degeneration and macular edema by administering the buffered antibody compositions of the disclosure.

The present invention relates to fusion molecules and chimeric molecules comprising two components: Ang2 antagonist peptides linked to VEGF binding moieties. Further disclosed are methods of treatingcancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema after retinal vein occlusion (RVO), diabetic macular edema (DME), ordiabetic retinopathy (DR) in a patient using the chimeric molecules.

Provided are methods, pharmaceutical formulations and kits thereof for the treatment and/or prevention of conditions mediated by neovascularization, abnormal angiogenesis, vascular permeability, or combinations thereof, of posterior and/or anterior tissues and fluids of the eye, including conditions associated with proliferative retinopathies, for example, diabetic retinopathy, age-related maculopathy, retinopathy of prematurity, retinopathy associated with macular edema, or retinopathy associated with sickle cell disease, using the topical administration of mecamylamine or a pharmaceutically acceptable salt thereof to the eye. Methods of preparing the pharmaceutical formulations are also provided.

The invention discloses a medicine composition for treating macular oedema. The medicine composition uses pyrethrum cinerariifolium roots, allyl amyl glycolate, lomatogonium carinthiacum, a rosette thistle herb, matairesinol and orientalol B as raw material medicines, is prepared according to proportions, can be prepared into various preparations by adopting a conventional preparation technology and is remarkable in effect of treating the macular oedema.